Kim, Hye RyunHye RyunKimSugawara, ShunichiShunichiSugawaraLee, Jong-SeokJong-SeokLeeKang, Jin-HyoungJin-HyoungKangInui, NaokiNaokiInuiHida, ToyoakiToyoakiHidaLee, Ki HyeongKi HyeongLeeYoshida, TatsuyaTatsuyaYoshidaTanaka, HiroshiHiroshiTanakaYang, Cheng-TaCheng-TaYangNishio, MakotoMakotoNishioOhe, YuichiroYuichiroOheTamura, TomohideTomohideTamuraYamamoto, NobuyukiNobuyukiYamamotoCHONG-JEN YUAkamatsu, HiroakiHiroakiAkamatsuTakahashi, ShigeruShigeruTakahashiNakagawa, KazuhikoKazuhikoNakagawa2023-09-042023-09-042023-08-282045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/634957ONO-4538-52/TASUKI-52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for the initial (first-line) treatment of patients with advanced non-squamous non-small cell lung cancer (nsNSCLC). At the interim analysis (minimum follow-up, 7.4 months), the independent radiology review committee-assessed progression-free survival was significantly longer in the nivolumab arm, but overall survival (OS) data were immature.enbevacizumab; chemotherapy; nivolumab; non-squamous non-small cell lung cancer; survival[SDGs]SDG3journal article10.1002/cam4.6348376415442-s2.0-85169072695https://api.elsevier.com/content/abstract/scopus_id/85169072695